LRMR NASDAQ
Larimar Therapeutics, Inc.
1W: -3.9%
1M: -23.5%
3M: -10.0%
YTD: -14.7%
1Y: -28.7%
3Y: -34.1%
5Y: -76.2%
$2.96
-0.10 (-3.27%)
Weekly Expected Move ±10.0%
$2
$3
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (35)
Larimar Therapeutics appoints John Harlow as COO
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Bank of New York Mellon Corp Takes Position in Larimar Therapeutics, Inc. $LRMR
BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
Brokers Set Expectations for LRMR Q1 Earnings
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
Larimar Therapeutics (NASDAQ:LRMR) Shares Up 8.2% Following Analyst Upgrade
Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22
Earnings Scheduled For March 19, 2026
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
127,500 Shares in Larimar Therapeutics, Inc. $LRMR Acquired by Cantor Fitzgerald L. P.
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Analysts
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar Therapeutics (NASDAQ:LRMR) Director Purchases $25,000,000.00 in Stock
Larimar Therapeutics stock dips after pricing $100M share offering
Larimar Therapeutics launches proposed $75 million public offering
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Larimar surges on FDA breakthrough status for lead asset
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of “Moderate Buy” by Analysts
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference